Literature DB >> 32852563

Remission of Anti-laminin 332 Mucous Membrane Pemphigoid Associated with Non-small Cell Lung Cancer after Therapy with Rituximab and Intravenous Immunoglobulin.

Evelyne Tarnowietzki1, Thorsten Peters, Lea Kraus, Enno Schmidt, Karin Scharffetter-Kochanek.   

Abstract

Entities:  

Keywords:  bullous pemphigoid; intravenous immunoglobulins; non-small-cell lung carcinoma; kalinin

Mesh：

Substances：

Year:  2020        PMID： 32852563      PMCID： PMC9274920          DOI： 10.2340/00015555-3621

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  8 in total

1.  A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid.

Authors:  S Goletz; C Probst; L Komorowski; W Schlumberger; K Fechner; N van Beek; M M Holtsche; A Recke; K B Yancey; T Hashimoto; F Antonicelli; G Di Zenzo; D Zillikens; W Stöcker; E Schmidt
Journal:  Br J Dermatol       Date:  2018-11-01       Impact factor: 9.302

Review 2.  The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators.

Authors:  Lawrence S Chan; A Razzaque Ahmed; Grant J Anhalt; Wolfgang Bernauer; Kevin D Cooper; Mark J Elder; Jo-David Fine; C Stephen Foster; Reza Ghohestani; Takashi Hashimoto; Thanh Hoang-Xuan; Gudula Kirtschig; Neil J Korman; Susan Lightman; Francina Lozada-Nur; M Peter Marinkovich; Bartly J Mondino; Catherine Prost-Squarcioni; Roy S Rogers; Jane F Setterfield; Dennis P West; Fenella Wojnarowska; David T Woodley; Kim B Yancey; Detlef Zillikens; John J Zone
Journal:  Arch Dermatol       Date:  2002-03

3.  Anti-epiligrin cicatricial pemphigoid and relative risk for cancer.

Authors:  C A Egan; Z Lazarova; T N Darling; C Yee; T Coté; K B Yancey
Journal:  Lancet       Date:  2001-06-09       Impact factor: 79.321

Review 4.  Malignancies in bullous pemphigoid: A controversial association.

Authors:  Riccardo Balestri; Michela Magnano; Michelangelo La Placa; Annalisa Patrizi; Luisa Angileri; Vera Tengattini; Federico Bardazzi
Journal:  J Dermatol       Date:  2015-10-05       Impact factor: 4.005

5.  Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid.

Authors:  M Witte; D Zillikens; I Shimanovich
Journal:  J Eur Acad Dermatol Venereol       Date:  2018-03-06       Impact factor: 6.166

6.  Anti-epiligrin cicatricial pemphigoid: clinical findings, immunopathogenesis, and significant associations.

Authors:  Conleth A Egan; Zelmira Lazarova; Thomas N Darling; Carole Yee; Kim B Yancey
Journal:  Medicine (Baltimore)       Date:  2003-05       Impact factor: 1.889

7.  Epiligrin, the major human keratinocyte integrin ligand, is a target in both an acquired autoimmune and an inherited subepidermal blistering skin disease.

Authors:  N Domloge-Hultsch; W R Gammon; R A Briggaman; S G Gil; W G Carter; K B Yancey
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

8.  Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up.

Authors:  Naveed Sami; Erik Letko; Sofia Androudi; Yassine Daoud; C Stephen Foster; A Razzaque Ahmed
Journal:  Ophthalmology       Date:  2004-07       Impact factor: 12.079
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.